Goldman Sachs analyst Richard Law CFA initiates coverage on $Protagonist Therapeutics (PTGX.US)$ with a hold rating, and sets the target price at $47.
According to TipRanks data, the analyst has a success rate of 33.3% and a total average return of 6.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Protagonist Therapeutics (PTGX.US)$'s main analysts recently are as follows:
Protagonist Therapeutics has potential for commercial success with its Phase 3 assets, although they are considered to provide 'limited' financial and mergers and acquisitions upside since they have already been licensed. The significant increase, over 400%, in the stock price of Protagonist over the past two years has been influenced by development progression and licensing agreements, reflecting the current market expectations from both assets.
Protagonist Therapeutics is utilizing its peptide technology platform to tackle disorders in hematology and immunology. The expectation is that the share price will rise as clinical risks are mitigated within its pipeline over the coming year, bolstered by multiple catalysts for rusfertide and JNJ-2113. Protagonist is positioned to offer oral alternatives in major blockbuster categories, which are presently overwhelmed by injectable solutions.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
高盛集团分析师Richard Law CFA首予$Protagonist Therapeutics (PTGX.US)$持有评级，目标价47美元。
根据TipRanks数据显示，该分析师近一年总胜率为33.3%，总平均回报率为6.1%。
此外，综合报道，$Protagonist Therapeutics (PTGX.US)$近期主要分析师观点如下：
Protagonist Therapeutics凭借其第三阶段资产有可能取得商业成功，尽管由于已经获得许可，这些资产被认为提供 “有限” 的财务和并购上升空间。Protaonist 股价在过去两年中大幅上涨，超过400％，这是受开发进展和许可协议的影响，反映了当前市场对这两种资产的预期。
Protagonist Therapeutics正在利用其肽技术平台来解决血液学和免疫学方面的疾病。预计在rusfertide和 JNJ-2113 的多种催化剂的推动下，随着未来一年其研发中的临床风险得到缓解，股价将上涨。Protagonist 有望在主要的重磅类别中提供口服替代品，这些类别目前可注射的溶液已不堪重负。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
